Leadership: Page 3
-
Biotech Spotlight
A new delivery method muscling its way into the RNA space
With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.
By Kelly Bilodeau • Nov. 8, 2023 -
How Big Pharma keeps the oncology engines hot with a host of strategies
From Merck and J&J to AbbVie and Eisai, the oncology field has stayed consistently devoted to churning out important therapies.
By Michael Gibney • Nov. 2, 2023 -
Trendline
Cell and gene therapies
How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.
By PharmaVoice staff -
Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says
Roivant Sciences CEO Matt Gline and Telavant CEO Frank Torti know Roivant’s position as buyers and sellers in the pharma industry, and they’re embracing those opportunities.
By Michael Gibney • Oct. 31, 2023 -
Q&A // Red Jacket winners 2023
Red Jacket: Adele Gulfo, a commercialization guru
With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.
By Karissa Waddick • Oct. 27, 2023 -
Q&A // Red Jacket winners 2023
Red Jacket: Helen Sabzevari, an immunotherapy pioneer
Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.
By Meagan Parrish • Oct. 27, 2023 -
Q&A // Red Jacket winners 2023
Red Jacket: Dr. Jeremy Levin, a transformational leader
A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.
By Michael Gibney • Oct. 27, 2023 -
The 2023 Red Jacket honorees
This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.
By Meagan Parrish • Oct. 27, 2023 -
Q&A // Red Jacket winners 2023
Red Jacket: Dr. Mark Goldberg, a clinical innovator
Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.
By Alexandra Pecci • Oct. 27, 2023 -
Q&A
Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’
The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.
By Michael Gibney • Oct. 19, 2023 -
The top biopharma conferences in 2024
A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.
By Ned Pagliarulo • Oct. 16, 2023 -
PharmaVoice 100
PharmaVoice 100s: Rare disease warriors
Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.
By Michael Gibney • Oct. 16, 2023 -
Opinion
Branded: The trademarks pharma leaders look up to
What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.
By PharmaVoice Staff • Oct. 13, 2023 -
Q&A
5 minutes with — IDEA Pharma’s Mike Rea
The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.
By Meagan Parrish • Oct. 11, 2023 -
Key upcoming events for pharma execs
Trade shows and events focused on the industry’s hot-button topics, technologies and trends.
By Meagan Parrish • Oct. 6, 2023 -
FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO
The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.
By Michael Gibney • Oct. 5, 2023 -
PharmaVoice 100
PharmaVoice 100s: Cancer care visionaries
Leaders shaping the future of oncology and cancer care through grit and determination in the face of one of healthcare’s greatest challenges.
By Michael Gibney • Oct. 2, 2023 -
The PharmaVoice 100: Trailblazers
Leaders who are going where no biopharma executive has gone before and changing the industry along the way.
By Michael Gibney • Sept. 29, 2023 -
Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk
A recent report showed how pharma’s bonuses pale in comparison to other industries, but several execs still rake in hefty packages.
By Michael Gibney • Sept. 28, 2023 -
PharmaVoice 100
PharmaVoice 100s: Standout execs
Leaders who’ve created unique strategies for thriving amid the heavy headwinds facing the industry.
By Meagan Parrish • Sept. 25, 2023 -
Sponsored by Astellas
For Astellas’ CMO, accelerating innovation means working at the edge of your comfort zone
Scientific discovery through new, breakthrough modalities is essential to solve current and future global health challenges – but the path is not easy nor well-defined.
Sept. 25, 2023 -
The 2023 PharmaVoice 100
This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.
By Julia Himmel • Sept. 19, 2023 -
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.
By Michael Gibney • Sept. 15, 2023 -
Catching up with 2022 PharmaVoice 100 honorees
Tapping into our growing community for expertise and inspiration.
By Meagan Parrish • Sept. 13, 2023 -
A tale of two biotechs — 2seventy, Regeneron announce C-suite shakeups
The biotech’s chief financial officer Robert Landry is retiring in February.
By Karissa Waddick • Sept. 12, 2023 -
Ex-Sanofi executive Sibold joins Madrigal as new CEO
Bill Sibold has led Sanofi's specialty care business unit for the past six years. He replaces Paul Friedman as head of the NASH drug developer.
By Ned Pagliarulo • Sept. 11, 2023